{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","upperLimit":"87","value":"71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Local control is defined as the arrest cancer growth at the site of origin. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy\n\nCetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor\n\nCisplatin: Cisplatin is an anti-cancer chemotherapy drug\n\nNab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation\n\nintensity-modulated radiation therapy: intensity-modulated radiation therapy","id":"OG000","title":"Phase II Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy"}],"paramType":"NUMBER","populationDescription":"12 patients from Phase I also participated in Phase II of this study. 25 patients enrolled in the phase II study with 3 patients withdrew from the study prior to treatment.","reportingStatus":"POSTED","timeFrame":"2 year","title":"Phase II 2-year Local Control","type":"SECONDARY","unitOfMeasure":"percentage of participants"}